Acute-on-chronic liver failure.
10.3350/cmh.2013.19.4.349
- Author:
Tae Yeob KIM
1
;
Dong Joon KIM
Author Information
1. Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
- Publication Type:Review
- Keywords:
Liver failure;
Acute-on-chronic liver failure;
Liver cirrhosis
- MeSH:
Chronic Disease;
Echocardiography;
Humans;
Liver Cirrhosis/complications;
Liver Failure/diagnosis/etiology/*pathology/prevention & control;
Liver Failure, Acute/diagnosis/etiology/*pathology/prevention & control;
Liver Transplantation;
Sepsis/complications
- From:Clinical and Molecular Hepatology
2013;19(4):349-359
- CountryRepublic of Korea
- Language:English
-
Abstract:
Acute-on-chronic liver failure (ACLF) is an increasingly recognized distinct disease entity encompassing an acute deterioration of liver function in patients with chronic liver disease. Although there are no widely accepted diagnostic criteria for ACLF, the Asia.Pacific Association for the Study of the Liver (APASL) and the American Association for the Study of Liver Disease and the European Association for the Study of the Liver (AASLD/EASL) consensus definitions are commonly used. It is obvious that the APASL and the AASLD/EASL definitions are based on fundamentally different features. Two different definitions in two different parts of the world hamper the comparability of studies. Recently, the EASL-Chronic Liver Failure Consortium proposed new diagnostic criteria for ACLF based on analyses of patients with organ failure. There are areas of uncertainty in defining ACLF, such as heterogeneity of ACLF, ambiguity in qualifying underlying liver disease, argument for infection or sepsis as a precipitating event, etc. Although the exact pathogenesis of ACLF remains to be elucidated, alteration of host response to injury, infection, and unregulated inflammation play important roles. The predisposition, infection/inflammation, response, organ failure (PIRO) concept used for sepsis might be useful in describing the pathophysiology and clinical categories for ACLF. Treatment strategies are limited to organ support but better understanding of the pathophysiology is likely to lead to discovery of novel biomarkers and therapeutic strategies in the future.
